Kidney Week 2012: Direct Renin Inhibition in Non-diabetic Kidney Disease (DRINK study)

An interim analysis from the DRINK trial was presented as an oral communication by Tang et al on Friday Nov 2nd. Seventy six non-diabetic patients with CKD stages 3-4 were randomized to receive either aliskiren or placebo in addition to a maximal dose of angiotensin receptor blockade (ARB). Primary outcome was CKD progression, ESRD or death. After a median follow-up time of 2 years there was no difference between groups in proteinuria, estimated GFR, progression to ESRD or death.  The rate of hyperkalemia was significantly increased in the intervention group.  Up to this point the study reveals no benefit  from aliskiren; however, the final results of the study will be presented in the future.

Post written by Dr. Magdalena Madero, eAJKD Contributor, and edited by Dr. Vinay Nair, eAKD Advisory Board member.

Check back for more eAJKD coverage of ASN’s Kidney Week 2012! Also, check out @eAJKD on Twitter for live updates!

Trackbacks

  1. [...] Direct Renin Inhibition in Non-diabetic Kidney Disease (DRINK study) [...]

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 4,223 other followers